Download PDF
Aktuelle Urol 2022; 53(04): 354-357
DOI: 10.1055/a-1032-8126
Fallbericht

Verumontanum-Mukosahyperplasie als Differenzialdiagnose eines Lokalrezidivs nach radikaler Prostatektomie[*]

Verumontanum mucosal hyperplasia as a differential diagnosis of a local recurrence following radical prostatectomy
K. Drosos
1   Klinik für Urologie und Kinderurologie, Klinikum Fulda
,
G. Köhler
2   Institut für Pathologie, Klinikum Fulda
,
I. Hofmann
1   Klinik für Urologie und Kinderurologie, Klinikum Fulda
,
T. Kälble
1   Klinik für Urologie und Kinderurologie, Klinikum Fulda
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Eine Verumontanum-Mukosahyperplasie (VMGH) ist eine benigne mikroazinäre proliferative Läsion, die ausschließlich im Verumontanum und in der posterioren Urethra auftritt und die zu den pseudoneoplastischen Imitatoren eines „low risk“ azinären Adenokarzinoms der Prostata zählt. Wir präsentieren den Fall eines 72-jährigen Patienten, bei dem 5 Jahre nach radikaler Prostatektomie wegen Adenokarzinom der Prostata pT2c pN0 cM0 R0, Gleason-Score: 3 + 3 = 6 der bildmorphologische Verdacht eines PSA-negativen Lokalrezidivs 3 × 2 cm im ehemaligen Prostatabett erhoben wurde. Das klinische Bild in Zusammenhang mit der histologischen Diagnostik führten zur Diagnose einer VMGH. Die VMGH ist eine kaum bekannte Differenzialdiagnose zum Lokalrezidiv eines Prostatakarzinoms bei einem PSA im Nullbereich, deren klinisches Bild dargestellt werden soll.

Abstract

Verumontanum mucosal gland hyperplasia (VMGH) is a benign microacinar proliferative lesion, which occurs exclusively in the verumontanum and the posterior urethra and is one of the lesions that may be confused with a low-risk adenocarcinoma of the prostate gland.

We present the case of a 72-year-old male patient who underwent radical prostatectomy due to an adenocarcinoma of the prostate gland (pT2c pN0 cM0 R0, Gleason Score: 3 + 3 = 6). Five years after the operation, we sonographically detected a 3x2 cm large tumour in the prostate bed. While our first assumption was a PSA-negative local recurrence following radical prostatectomy, a comprehensive histological examination along with the clinical evaluation led us to the diagnosis of a VMGH. VMGH is a less well-known differential diagnosis of PSA-negative local recurrence following radical prostatectomy, whose clinical manifestation should be presented.

Schlüsselwörter

Adenokarzinom der Prostata - Lokalrezidiv - Verumontanum-Mukosahyperplasie - Benigne „mimics“ des Prostatakarzinoms

Keywords

verumontanum mucosal gland hyperplasia - adenocarcinoma of the prostate gland - local recurrence - benign mimics of prostate cancer

* Der folgende Fallbericht wurde mündlich am 23.05.2019 im Rahmen der 60 Jahrestagung der Südwestdeutschen Gesellschaft für Urologie in Stuttgart vorgetragen.




Publication History

Article published online:
03 December 2019

© 2019. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Gagucas RJ, Brown RW, Wheeler TM. Verumontanum mucosal gland hyperplasia. The American Journal of Surgical Pathology 1995; 19: 30-36
    CrossrefPubMedGoogle Scholar
  • 2 Gaudin PB, Wheeler TM, Epstein JI. Verumontanum mucosal gland hyperplasia in prostatic needle biopsy specimens. A mimic of low grade prostatic adenocarcinoma. The American Journal of Clinical Pathology 1995; 104: 620-626
    CrossrefPubMedGoogle Scholar
  • 3 Trpkov K. Benign mimics of prostatic adenocarcinoma. Modern Pathology 2018; 31: 22-46
    CrossrefPubMedGoogle Scholar
  • 4 Parson JK, Gage WR, Nelson WG. et al. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology 2001; 58: 619-624
    CrossrefPubMedGoogle Scholar
  • 5 Evans AJ. Α-Methyl acyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies. Journal of Clinical Pathology 2003; 56 (12) 892-897
    CrossrefPubMedGoogle Scholar
  • 6 Allan C, Epstein J. Nephrogenic adenoma of the prostatic urethra: a mimicker of prostate adenocarcinoma. The American Journal of Surgical Pathology 2001; 25 (06) 802-808
    CrossrefPubMedGoogle Scholar
  • 7 Skinnider BF, Oliva E, Young RH. et al. Expression of alpha-methylacyl-CoA racemase (P504S) in nephrogenic adenoma: a significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma. The American Journal of Surgical Pathology 2004; 28: 701-705
    CrossrefPubMedGoogle Scholar
  • 8 Pound CR, Christens-Barry OW, Gurganus RT. et al. Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. The Journal of Urology 1999; 162: 1337-1340
    CrossrefPubMedGoogle Scholar
  • 9 Oefelein MG, Smith N, Dalton D. et al. The Incidence of Prostate Cancer Progression with Undetectable Serum Prostate Specific Antigen in a Series of 394 Radical Prostatectomies. The Journal of Urology 1995; 154: 2128-2131
    CrossrefPubMedGoogle Scholar
  • 10 Montironi R, Scarpelli N, Mazzucchelli R. et al. Retracted: The spectrum of morphology in non‐neoplastic prostate including cancer mimics. Histopathology 2011; 60: 41-58
    CrossrefPubMedGoogle Scholar
  • 11 Bostwich DG, Cheng L. Urologic Surgical Pathology. Elsevier; 2013. 3rd ed. Chapter 8, 398
    Google Scholar